C84.62
Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes
Clinical Classification Guidelines
Medical Intelligence & Overview
Anaplastic large cell lymphoma (ALCL), ALK-positive, is a type of non-Hodgkin lymphoma, a cancer that originates in the lymphatic system. Specifically, this form affects the lymph nodes located within the chest (intrathoracic lymph nodes). It is characterized by the presence of large abnormal lymphocytes and the expression of the anaplastic lymphoma kinase (ALK) protein, which influences the behavior of the disease. ALK-positive ALCL often occurs in children and young adults but can affect individuals of any age. The disease tends to be aggressive but may respond well to specific treatments when diagnosed early.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to the abnormal expression of the ALK protein Chromosomal rearrangements involving the ALK gene, such as the translocation t(2;5) Potential environmental factors, though no definitive cause has been identified Inherent genetic predispositions in some cases
Key Symptoms: Swollen lymph nodes in the chest area, which may be painless Cough or shortness of breath due to chest involvement Chest pain or discomfort Fever that persists over time Unexplained weight loss Fatigue and general feelings of weakness Night sweats Possible signs of infection or other complications due to compromised immune function
Diagnostic & Treatment
Diagnosis Path: Diagnosing ALK-positive anaplastic large cell lymphoma involves several steps: - **Physical Examination**: Checking for swollen lymph nodes and other symptoms. - **Imaging Tests**: Chest X-rays, CT scans, or PET scans to locate enlarged lymph nodes within the thoracic cavity. - **Biopsy**: Extracting a tissue sample from the affected lymph node to examine under a microscope. - **Histopathological Analysis**: Identifying the characteristic large, abnormal lymphocytes. - **Immunohistochemistry**: Testing for specific markers like ALK protein to confirm ALK-positive status. - **Molecular Tests**: Detecting genetic rearrangements or mutations involving the ALK gene. These diagnostic tools help distinguish ALK-positive ALCL from other lymphomas and guide treatment options.
Treatment Protocols: Treatment strategies for ALK-positive anaplastic large cell lymphoma typically include a combination of therapies: - **Chemotherapy**: Regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) are commonly used. - **Targeted Therapy**: Drugs targeting the ALK protein, like crizotinib, have shown effectiveness in ALK-positive cases. - **Radiation Therapy**: May be employed to manage localized disease or relieve symptoms. - **Stem Cell Transplantation**: Considered in cases of relapse or refractory disease. - **Supportive Care**: Managing side effects and ensuring quality of life during treatment. The choice of treatment depends on the stage of the disease, patient health, and specific disease characteristics. Close coordination among a specialized medical team is essential for optimal care.
Clinical Advice & FAQs
Billing Guidance
Is C84.62 a billable ICD-10 code?
Yes, C84.62 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C84.62?
Clinical documentation must specify the nature of Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes and any associated comorbidities for accurate reporting.
Cite this Clinical Reference